Payment overview · 2025
General Payments
$2,327.75
105 reported records · 17 companies
Healthcare provider profile · identity verified
Julio V Guzman, MD
Allopathic & Osteopathic Physicians|Family Medicine · LOS ANGELES, CA · NPI 1184653628
Verified facts
What the public records show
CMS Open Payments records show Julio V Guzman, MD received $2,327.75 in general payments during 2025 across 105 reported records.
ABBVIE INC. accounted for 23.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 26 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Gemtesa, Jardiance, Kerendia, Linzess, Mounjaro, Ozempic, Rexulti.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 281 claims for Linzess by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 222 claims for Farxiga by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 238 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 271 claims for Jardiance by this doctor in 2024.
IRONWOOD PHARMACEUTICALS, INC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Linzess as an associated drug or biological on 1209 records involving 1184 distinct recipient NPIs. Public Medicare Part D data also shows 281 claims for Linzess by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 271 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Trulicity by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Rexulti by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 236 claims for Ozempic by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Rexulti by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 154 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $546.53 | 23.5% | 23 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $302.72 | 13.0% | 13 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $262.16 | 11.3% | 12 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $188.75 | 8.1% | 9 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $187.03 | 8.0% | 8 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $174.97 | 7.5% | 8 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $137.01 | 5.9% | 10 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $127.02 | 5.5% | 5 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $100.21 | 4.3% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $70.73 | 3.0% | 3 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $59.54 | 2.6% | 3 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $54.53 | 2.3% | 2 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $34.74 | 1.5% | 1 | 2025 |
| Smith+Nephew, Inc. | Unresolved — no canonical attribution shown | $28.13 | 1.2% | 1 | 2025 |
| IRONWOOD PHARMACEUTICALS, INC | Unresolved — no canonical attribution shown | $21.01 | 0.9% | 1 | 2025 |
| Azurity Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.96 | 0.7% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.71 | 0.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,322.90 | 104 |
| Education | $4.85 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $229.50 | 10 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $211.92 | 10 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $199.20 | 9 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $188.75 | 9 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $187.03 | 8 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC., IRONWOOD PHARMACEUTICALS, INC | $174.23 | 7 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $162.78 | 6 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $159.07 | 7 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $146.15 | 6 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $142.28 | 6 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $133.34 | 5 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $133.30 | 6 | 2025 |
Source payment records
|
|||||
| Tresiba Normalized: tresiba |
Drug | Novo Nordisk Inc | $133.30 | 6 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $103.09 | 5 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $100.21 | 4 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $73.93 | 3 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $71.76 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $63.08 | 7 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $63.08 | 7 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $59.54 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $51.60 | 2 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $34.74 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $31.76 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $28.68 | 1 | 2025 |
Source payment records
|
|||||
| COLLAGENASE SANTYL Normalized: collagenase santyl |
Drug | Smith+Nephew, Inc. | $28.13 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $15.71 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 222 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 154 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 271 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 238 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 281 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 35 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 236 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
281 | 71 |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
53 | 35 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
222 | 50 |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
238 | 52 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
271 | 64 |
| IRONWOOD PHARMACEUTICALS, INC Exact reporting entity; no affiliate inference |
2025 | Linzess open payments reported associated product |
CMS Open Payments — General Payments 1209 supporting records · 1184 recipient NPIs · example record 1227653589 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
281 | 71 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
271 | 64 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
48 | 17 |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
236 | 67 |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
154 | 46 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 696 | 184 |
| Amlodipine Besylate | Amlodipine Besylate | 426 | 114 |
| Losartan Potassium | Losartan Potassium | 418 | 112 |
| Metformin Hcl | Metformin Hcl | 317 | 94 |
| Omeprazole | Omeprazole | 291 | 101 |
| Linzess | Linaclotide | 281 | 71 |
| Furosemide | Furosemide | 274 | 72 |
| Tamsulosin Hcl | Tamsulosin Hcl | 273 | 77 |
| Jardiance | Empagliflozin | 271 | 64 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 271 | 87 |
| Levothyroxine Sodium | Levothyroxine Sodium | 257 | 57 |
| Gabapentin | Gabapentin | 243 | 77 |
| Kerendia | Finerenone | 238 | 52 |
| Ozempic | Semaglutide | 236 | 67 |
| Lisinopril | Lisinopril | 224 | 59 |
| Farxiga | Dapagliflozin Propanediol | 222 | 50 |
| Tramadol Hcl | Tramadol Hcl | 218 | 43 |
| Pantoprazole Sodium | Pantoprazole Sodium | 207 | 67 |
| Ezetimibe | Ezetimibe | 206 | 58 |
| Vascepa | Icosapent Ethyl | 204 | 59 |
| Pioglitazone Hcl | Pioglitazone Hcl | 170 | 39 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 160 | 58 |
| Gemtesa | Vibegron | 154 | 46 |
| Lorazepam | Lorazepam | 153 | 24 |
| Ibuprofen | Ibuprofen | 149 | 48 |
| Raloxifene Hcl | Raloxifene Hcl | 148 | 44 |
| Carvedilol | Carvedilol | 145 | 35 |
| Icosapent Ethyl | Icosapent Ethyl | 135 | 60 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 130 | 34 |
| Metoprolol Succinate | Metoprolol Succinate | 121 | 32 |
| Diclofenac Sodium | Diclofenac Sodium | 120 | 46 |
| Pregabalin | Pregabalin | 120 | 36 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 118 | 40 |
| Tradjenta | Linagliptin | 117 | 23 |
| Meclizine Hcl | Meclizine Hcl | 115 | 38 |
| Trazodone Hcl | Trazodone Hcl | 113 | 45 |
| Meloxicam | Meloxicam | 112 | 41 |
| Fluticasone Propionate | Fluticasone Propionate | 111 | 36 |
| Nifedipine Er | Nifedipine | 111 | 35 |
| Quetiapine Fumarate | Quetiapine Fumarate | 110 | 27 |
| Memantine Hcl | Memantine Hcl | 107 | 34 |
| Alendronate Sodium | Alendronate Sodium | 105 | 36 |
| Donepezil Hcl | Donepezil Hcl | 105 | 33 |
| Glipizide | Glipizide | 98 | 30 |
| Escitalopram Oxalate | Escitalopram Oxalate | 95 | 43 |
| Famotidine | Famotidine | 95 | 26 |
| Labetalol Hcl | Labetalol Hcl | 91 | 33 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 90 | 37 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 86 | 24 |
| Clopidogrel | Clopidogrel Bisulfate | 85 | 18 |
| Naproxen | Naproxen | 84 | 24 |
| Alprazolam | Alprazolam | 79 | 14 |
| Hydralazine Hcl | Hydralazine Hcl | 78 | 16 |
| Megestrol Acetate | Megestrol Acetate | 78 | 21 |
| Trijardy Xr | Empaglifloz/Linaglip/Metformin | 78 | 16 |
| Finasteride | Finasteride | 77 | 28 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 77 | 27 |
| Eliquis | Apixaban | 71 | 16 |
| Azithromycin | Azithromycin | 68 | 54 |
| Ondansetron Odt | Ondansetron | 68 | 29 |
| Misoprostol | Misoprostol | 67 | 24 |
| Glimepiride | Glimepiride | 66 | 20 |
| Duloxetine Hcl | Duloxetine Hcl | 62 | 23 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 60 | 54 |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 60 | 16 |
| Fluoxetine Hcl | Fluoxetine Hcl | 58 | 19 |
| Fenofibrate | Fenofibrate Nanocrystallized | 57 | 25 |
| Temazepam | Temazepam | 56 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 56 | 17 |
| Clonidine Hcl | Clonidine Hcl | 53 | suppressed |
| Prolia | Denosumab | 53 | 35 |
| Dutasteride | Dutasteride | 52 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 50 | 19 |
| Lidocaine | Lidocaine | 50 | 13 |
| Benazepril Hcl | Benazepril Hcl | 48 | 15 |
| Trulicity | Dulaglutide | 48 | 17 |
| Metformin Hcl Er | Metformin Hcl | 47 | 19 |
| Methylprednisolone | Methylprednisolone | 46 | 35 |
| Clotrimazole | Clotrimazole | 44 | 17 |
| Procto-Med Hc | Hydrocortisone | 44 | 13 |
| Dicyclomine Hcl | Dicyclomine Hcl | 41 | 17 |
| Metoclopramide Hcl | Metoclopramide Hcl | 39 | suppressed |
| Fluconazole | Fluconazole | 38 | 15 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 38 | 17 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 36 | 21 |
| Mounjaro | Tirzepatide | 35 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 35 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 34 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 34 | 11 |
| Dexlansoprazole Dr | Dexlansoprazole | 33 | suppressed |
| Clonazepam | Clonazepam | 32 | suppressed |
| Entresto | Sacubitril/Valsartan | 32 | suppressed |
| Atenolol | Atenolol | 31 | suppressed |
| Lactulose | Lactulose | 30 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 30 | suppressed |
| Celecoxib | Celecoxib | 29 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 29 | 20 |
| Gvoke Hypopen 2-Pack | Glucagon | 29 | 22 |
| Ropinirole Hcl | Ropinirole Hcl | 29 | suppressed |
| Allopurinol | Allopurinol | 28 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 27 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 27 | suppressed |
| Simvastatin | Simvastatin | 27 | suppressed |
| Januvia | Sitagliptin Phosphate | 26 | suppressed |
| Latanoprost | Latanoprost | 26 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 26 | suppressed |
| Hydrocortisone | Hydrocortisone | 25 | 11 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 25 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 24 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 23 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 23 | suppressed |
| Ketoconazole | Ketoconazole | 22 | 11 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 22 | suppressed |
| Rexulti | Brexpiprazole | 22 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 21 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 21 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 20 | 13 |
| Chlorthalidone | Chlorthalidone | 20 | suppressed |
| Novolog Flexpen | Insulin Aspart | 20 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 20 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 19 | suppressed |
| Cephalexin | Cephalexin | 19 | 18 |
| Terazosin Hcl | Terazosin Hcl | 19 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 18 | suppressed |
| Evenity (2 Syringes) | Romosozumab-Aqqg | 18 | suppressed |
| Lovastatin | Lovastatin | 18 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 17 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 17 | suppressed |
| Enulose | Lactulose | 17 | suppressed |
| Myrbetriq | Mirabegron | 17 | suppressed |
| Topiramate | Topiramate | 17 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 17 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 16 | suppressed |
| Lansoprazole | Lansoprazole | 16 | suppressed |
| Timolol Maleate | Timolol Maleate | 16 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 15 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 15 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 15 | suppressed |
| Nitroglycerin | Nitroglycerin | 15 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 15 | suppressed |
| Amoxicillin | Amoxicillin | 14 | 11 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 14 | suppressed |
| Humalog Kwikpen U-200 | Insulin Lispro | 14 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 14 | suppressed |
| Loperamide | Loperamide Hcl | 14 | suppressed |
| Minoxidil | Minoxidil | 14 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 14 | suppressed |
| Spironolactone | Spironolactone | 14 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 14 | suppressed |
| Xarelto | Rivaroxaban | 14 | suppressed |
| Baclofen | Baclofen | 13 | suppressed |
| Bupropion Xl | Bupropion Hcl | 13 | suppressed |
| Carisoprodol | Carisoprodol | 13 | suppressed |
| Cinacalcet Hcl | Cinacalcet Hcl | 13 | suppressed |
| Exforge | Amlodipine Besylate/Valsartan | 13 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 13 | suppressed |
| Olanzapine | Olanzapine | 13 | suppressed |
| Telmisartan | Telmisartan | 13 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 13 | suppressed |
| Xifaxan | Rifaximin | 13 | suppressed |
| Acyclovir | Acyclovir | 12 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 12 | suppressed |
| Colchicine | Colchicine | 12 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 12 | suppressed |
| Mirtazapine | Mirtazapine | 12 | suppressed |
| Risperidone | Risperidone | 12 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Aliskiren | Aliskiren Hemifumarate | 11 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 11 | suppressed |
| Digoxin | Digoxin | 11 | suppressed |
| Dorzolamide Hcl | Dorzolamide Hcl | 11 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 11 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 11 | suppressed |
| Unifine Pentips | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,327.75 · 105 records | ABBVIE INC. | AIRSUPRA, BREZTRI, CAPLYTA, COLLAGENASE SANTYL, CREON, EVENITY, FARXIGA, GEMTESA, GVOKE HYPOPEN, IBSRELA, JARDIANCE, Kerendia, LEQVIO, LINZESS, MOUNJARO, OTEZLA, Ozempic, QULIPTA, REPATHA, REXULTI, Rybelsus, Tresiba, UBRELVY, VRAYLAR, Wegovy, ZEPBOUND | 14 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error